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In multitarget drug design, it is critical to identify active and inactive compounds against
a variety of targets and antitargets. Multitarget strategies thus test the limits of available
technology, be that in screening large databases of compounds vs. a large number of
targets, or in using in silico methods for understanding and reliably predicting these
pharmacological outcomes. In this paper, we have evaluated the potential of several
in silico approaches to predict the target, antitarget and physicochemical profile of
(S)-blebbistatin, the best-known myosin II ATPase inhibitor, and a series of analogs
thereof. Standard and augmented structure-based design techniques could not recover
the observed activity profiles. A ligand-based method using molecular fingerprints
was, however, able to select actives for myosin II inhibition. Using further ligand- and
structure-based methods, we also evaluated toxicity through androgen receptor binding,
affinity for an array of antitargets and the ADME profile (including assay-interfering
compounds) of the series. In conclusion, in the search for (S)-blebbistatin analogs,
the dissimilarity distance of molecular fingerprints to known actives and the computed
antitarget and physicochemical profile of the molecules can be used for compound
design for molecules with potential as tools for modulating myosin II and motility-related
diseases.
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INTRODUCTION
Multitarget drug design attempts to rationalize interactions with targets and antitargets. A fine
balance is required given that a compound needs to have the right amount of promiscuity, i.e.,
selectivity. If only one target is hit, an alternative pathway may evolve around the target and
the compound may end up lacking efficacy. Too much promiscuity or non-specific interactions,
however, will lead to side-effects or toxicity related to antitargets.
Computational methods are central to the ability to predict interactions between compounds
and targets given their ability to use a large amount of data on both. They help to prioritize
compounds for development or help in target profiling. Several methods can be used, among them
structure-based design, as well as filters and bioinformatics approaches (Schneider, 2018).
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This paper focuses on the use of such techniques for
the multitarget (target and antitargets) design of inhibitors
of myosins, the ATP-driven molecular motor proteins of
the eukaryotic cell (Sweeney and Houdusse, 2010). The
pyrroloquinolinone (S)-blebbistatin, (S)-1 in Figure 1, is a cell-
permeable, micromolar ATPase cycle inhibitor of myosin II.
It is the only available myosin II-specific inhibitor: it does
not modulate myosins I, V, and X (Limouze et al., 2004).
Since its discovery (Cheung et al., 2001), (S)-blebbistatin has
therefore been used extensively as a tool for understanding
the function of myosin II (Coluccio, 2008; Vicente-Manzanares
et al., 2009; Bond et al., 2012), and for dissecting its role
in pathological processes such as invasion and in malignant
disease (Duxbury et al., 2004; Betapudi et al., 2006; Derycke
et al., 2011; Ivkovic et al., 2012), viral infections (Lehmann
et al., 2005; Kumakura et al., 2015; Gao et al., 2016),
bacterial infections (Lum and Morona, 2014), glaucoma
(Zhang and Rao, 2005), progressive renal disease (Si et al.,
2010), and methamphetamine use relapse (Young et al.,
2016).
(S)-blebbistatin ((S)-1) bears deficiencies that encumber
its use in sophisticated biological model systems or as
a lead for the development of pharmaceutical tools: its
potency is too low (micromolar range) (Verhasselt et al.,
2017a,b,c), it is toxic to certain cell lines and organisms
(Kolega, 2004; Sakamoto et al., 2005; Mikulich et al., 2012),
and it has poor water solubility (Képiró et al., 2012, 2014;
Swift et al., 2012; Verhasselt et al., 2017a,b,c). Derivatives
with improved aqueous solubility (Várkuti et al., 2016;
Verhasselt et al., 2017a,b) and reduced toxicity have been
prepared. However, despite the clinical interest in myosin II
inhibitors and significant efforts by several groups (Lucas-
Lopez et al., 2008; Lawson et al., 2011; Verhasselt et al.,
2017a,c), blebbistatin analogs with higher potency have thus
far not been prepared. The main reason for this failure is the
empirical observation that selectivity and affinity of myosin
inhibitors cannot be rationalized from analysis of the residues
lining the binding pocket (Sirigu et al., 2016; Verhasselt et al.,
2017b,c). Other factors, such as the kinetics of the chemo-
mechanical cycle must play an important role in myosin ligand
discrimination.
As conventional medicinal chemistry approaches have failed
to identify (S)-blebbistatin analogs with improved development
FIGURE 1 | The myosin II ATPase inhibitor (S)-blebbistatin ((S)-1): structure, numbering system, strengths and deficiencies.
profiles, we evaluated the potential of a variety of structure-
based and ligand-based techniques. Focus was first put on the
recovery of active blebbistatin derivatives among a series of
analogs, where some methods clearly achieved better outcomes
than others. Filters for absorption, distribution, metabolism,
and excretion (ADME) profiles and PAINS compounds (non-
specific, assay-interfering compounds) were also evaluated.
Antitarget effects were studied using a battery of antitarget
proteins with physiological significance for myosin inhibitors,
including the androgen receptor involved in hormonal systems
and skeletal muscle differentiation (Rayment et al., 1993;
Wannenes et al., 2008), the pregnane X receptor (PXR)
involved in eﬄux of xenobiotics, sulfotransferase (SULT) and
cytochrome P450 (CYP) isoforms involved in humanmetabolism
of substances.
METHODS
Compounds
The library under study contains 19 compounds (Table 1).
Structure-activity data were taken from our earlier reports
on blebbistatin analogs (Verhasselt et al., 2017a,b,c). These
activity data were obtained using one assay protocol and
were collected by one observer. Synthetic protocols and
generation of ATPase inhibitory activity data against rabbit
skeletal-muscle myosin in an in-house developed assay are
described in these papers. The studied library contains both
compounds that are active and inactive against myosin II ATPase
activity.
Docking
The crystal structure of Dictyostelium discoideum myosin II,
1YV3 (Allingham et al., 2005), was selected and downloaded
from the Protein Data bank (Berman et al., 2000). The
resolution of the crystal structure determination was
2.00 Ångström and contained the co-crystallized ligand
(S)-blebbistatin ((S)-1, BIT), also called (-)-1-phenyl-1,2,3,4-
tetrahydro-4-hydroxypyrrolo[2,3-b]-7-methylquinolin-4-one,
or (S)-(3a)-hydroxy-6-methyl-1-phenyl-3,3a-dihydro-1H-
pyrrolo[2,3-b]quinolin-4(2H)-one. The sequences of rabbit
(Oryctolagus cuniculus) and D. discoideum were aligned and
a strong agreement of over 81.8% identity in the residues
of the binding site was found. The binding site (site AC5
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TABLE 1 | Studied compounds: (S)-blebbistatin ((S)-1) and analogs, inhibitory
potency against rabbit skeletal muscle myosin II ATPase activity and references.
Compound IC50
(µM)
References
R =
(S)-1 ((S)-Blebbistatin) H 2.16 Verhasselt et al.,
2017b
(S)-2 3
′
-CN 48.5 Verhasselt et al.,
2017b
(S)-3 3
′
-COOH ≥300 Verhasselt et al.,
2017b
(S)-4 3
′
-CONH2 ≥300 Verhasselt et al.,
2017b
(S)-5 3
′
-OAllyl 9.41 Verhasselt et al.,
2017a
(S)-6 3
′
-OH 19.3 Verhasselt et al.,
2017b
(S)-7 3
′
-OAcryl 57.6 Verhasselt et al.,
2017a
(S)-8 3
′
-NH2 14.1 Verhasselt et al.,
2017b
(S)-9 3
′
-
OPropanoyl
23.5 Verhasselt et al.,
2017a
(S)-10 3
′
-
NHPropanoyl
≥300 Verhasselt et al.,
2017a
(S)-11 3
′
-NHAcryl ≥300 Verhasselt et al.,
2017a
(S)-12 4
′
-OAllyl 0.94 Verhasselt et al.,
2017a
(S)-13 4
′
-OH 13.5 Verhasselt et al.,
2017a
(S)-14 4
′
-OBn ≥300 Verhasselt et al.,
2017a
(S)-18 4
′
-NH2 9.22 Várkuti et al., 2016
(S)-19 4
′
-NO2 1.96 Képiró et al., 2014
(S)-15 ≥300 Verhasselt et al.,
2017b
(S)-16 19.0 Verhasselt et al.,
2017b
(Continued)
TABLE 1 | Continued
Compound IC50
(µM)
References
(S)-17 17.8 Verhasselt et al.,
2017b
in pdb) consists of Phe 239, Gly 240, Tyr 261, Leu 262,
Leu 263, Ser 456, Glu 467, Cys 470, Tyr 634, Gln 637, and
Leu 641 for D. discoideum, which correspond to Phe 239,
Gly 240, Tyr 261, Leu 262, Leu 263, Asp 456, Glu 467, Cys
470, Phe 634, Gln 637, and Leu 641 in rabbit myosin II
heavy chain. The structure alignment is available in Table S1.
Crucial residues are conserved in the binding site of myosin
II heavy chain between these species, as well as with human,
with the rest of the pocket consisting of hydrophobic areas
that are also similar for these species. Also important, the
same experimental response to blebbistatin was observed by the
enzyme of all three species (Table S2). Docking calculations with
and without crystallographic water molecules were conducted
using GOLD (v5.22) (Jones et al., 1997) and Glide (Glide, 2017).
For Glide, the protein structure was prepared with Maestro,
and the XP scoring function, flexible ligand, and rigid protein
settings were used, as well as no Epik penalties (state penalties
based on predicted populations in solution for the structures it
generates) were applied. VdW radii of protein atoms was scaled
by 1 (i.e., not scaled), and the charge cutoff for polarity was
0.25, with the grid containing 10 Å in x, y, and z, centered
on 22.37, 38.35, 37.18, for the inner box, and 30 Å in x, y,
and z for the outer box. For GOLD, the structure of myosin
II was prepared with MOE2016 software. The docking protocol
(protein structure and docking conditions) was validated by re-
docking the crystallographic ligand. Blebbistatin analogs were
built and their energy was minimized using MOE2016 software
and then docked into the allosteric binding site in the myosin
II S1 motor domain, using the validated docking protocols. For
the docking simulations with GOLD a search space sphere with
a radius of 15 Å was defined as the binding pocket of myosin II,
centered on the crystallographic coordinates of the oxygen atom
of Ser456 residue. Docking calculations were performed using
the following parameters: number of islands = 5, population
size = 100, number of operations = 100,000, a niche size = 2,
and a selection pressure = 1.1. All H-bond donors/acceptors
were treated as solvent accessible. For each compound 1,000
runs were performed. Flip of pyramidal N, amide bonds, and
ring corners were allowed. To score the compounds, the scoring
function was used after being validated. The search efficiency
was set to 100%. Ten top docking poses were retained for each
compound.
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Antitargets
The battery of antitargets that have physiological significance
for experiments involving blebbistatin was assessed with three
different docking programs (Schrödinger Glide XP, Glide, 2017,
Autodock4, Morris et al., 1998, and Autodock Vina, Trott and
Olson, 2010), each with its own scoring function, as described
in previous work (García-Sosa and Maran, 2014). The collected
interactions against PXR (Watkins et al., 2003), SULT (Lu et al.,
2005), CYP 2A6 (Yano et al., 2005), CYP 2C9 (Williams et al.,
2003), and CYP 3A4 (Yano et al., 2004) were calculated and then
scored and visualized. The structure of the androgen receptor,
1T7R (Hur et al., 2004), with a resolution of 1.4 Ångströms,
was downloaded from the Protein Databank (Berman et al.,
2000). It contained the co-crystallized ligand dihydrotestosterone
(DHT), a known active. Hydrogens were added and the proteins’
structure titrated with Maestro1
ADME
FAF (Free ADME-Tox Filtering Tool) filters were used to calculate
ADME parameters for the compounds (Lagorce et al., 2008).
Briefly, the filters are based on searches of substructures within
ligands and previous knowledge of PAINs, reactive groups,
solubility, Lipinski’s, Veber’s, and Egan’s rules, among others.
Fingerprints
Dissimilarity distance calculations between compounds were
carried out using extended connectivity fingerprints (ECFP), as
1(2017). Maestro. Schrödinger, LLC: New York. https://www.schrodinger.com/
maestro.
implemented in ChemAxon2. Compounds were separated into
a group of actives (experimental IC50 <10µM) and a group of
inactives (IC50 > 10µM). Dissimilarity distances were calculated
by Tanimoto coefficients between individual compounds, and
also between each compound and the average distance to all the
actives (both including and excluding (called “actives-self ”) said
compound if in that group) or to all the inactives.
RESULTS AND DISCUSSION
The structures of the compounds under study, i.e., (S)-
blebbistatin ((S)-1) and a series of structural analogs, are
presented in Table 1 (Verhasselt et al., 2017a,b).
Docking
Docking of the blebbistatin analogs under study (Table 2,
Figure 2) was carried out with and without crystallographic
waters in the Myosin II binding site using GOLD 5.22 and
Glide XP software. The docked blebbistatin library occupied
the same region and displayed the same binding mode as
the co-crystallized ligand. Figure 2 shows the best binding
poses obtained for five (S)-blebbistatin analogs (results obtained
without crystallographic waters). All docked (S)-blebbistatin
analogs occupying the same region of the binding pocket, had
orientations highly resembling the crystallographic ligand, and
were able to establish two hydrogen bonds between their OH
moiety and Leu 262 and Gly 240 in the myosin II binding pocket.
2(2017). Instant JChem v. 5.6.0. ChemAxon Ltd.: Budapest, Hungary. http://www.
chemaxon.com.
TABLE 2 | Experimental inibitory activities and docking Scores (with and without crystallographic waters) obtained with Glide XP and GOLD Chemplp.
Compounda IC50 (µM) Glide XP score with waters
b Glide XP score without watersb ChemPLP without watersc ChemPLP with watersc
(S)-1 2.16 −13.07 −12.65 95.5 108.23
(S)-2 48.5 −12.24 −12.79 95.9 108.67
(S)-3 ≥300 −13.91 0 93.6 106.37
(S)-4 ≥300 −13.55 −13.03 92.9 105.62
(S)-5 9.41 −13.80 −12.15 106.88 119.55
(S)-6 19.3 −13.91 −13.03 97.9 110.65
(S)-7 57.6 −13.42 0 107.18 119.82
(S)-8 14.1 −11.93 −14.04 97.9 110.73
(S)-9 23.5 −12.97 −12.45 106.68 119.46
(S)-10 ≥300 −13.86 0 108.31 120.97
(S)-11 ≥300 −13.72 0 110.36 123.04
(S)-12 0.94 −13.01 −12.49 104.7 117.47
(S)-13 13.53 −12.01 −13.14 95.22 107.9
(S)-14 ≥300 −13.30 0 116.16 128.92
(S)-15 ≥300 −12.70 0 102.39 115.08
(S)-16 19.04 −12.16 −12.83 103.49 116.19
(S)-17 17.81 −12.45 −12.83 100 112.68
(S)-18 9.22 −12.19 −13.23 95.01 107.73
(S)-19 1.96 −12.05 −12.19 87.43 100.08
aStructures of compounds (S)-1 to (S)-19 are shown in Table 1. bGlide XP score (kcal/mol). cChemPLP (GOLD fitness score).
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FIGURE 2 | Best docking poses for five (S)-blebbistatin analogs (cyan) inside
the myosin II binding pocket (in red surface and gray sticks) without water
molecules obtained using GOLD 5.22 software: (A) (S)-1; (B) (S)-5; (C) (S)-12;
(D) (S)-18; (E) (S)-19.
From these docking results, it is not possible to anticipate the
structural features responsible for the loss or the improvement
of the inhibitory activity (Table 2) of (S)-blebbistatin analogs.
Also, the docking scores are not able to differentiate between
actives and inactives, e.g., in the absence of waters for the
most active compound (S)-12 (IC50 = 0.94µM), we obtain a
score of 104.7 with GOLD (or −12.49 with Glide), but for the
second most active compound (S)-19, (IC50 = 1.96µM), the
lowermost score of 87.4 is obtained with GOLD (or −12.19
with Glide). No correlation was found between scores and
activity.
The importance of including crystallographic waters
in the analysis is illustrated in Figure 3. From these
illustrations, it is also clear that the binding site is very
tight. The path toward it from the surface of the protein
is moreover very constrained, with a nearly occluded
mouth leading to a thin channel into the small binding
pocket.
Given the above negative individual results and binding
site considerations, consensus methods were evaluated to
find correlations between experimental activity data and
docking scores. Docking results of the library of (S)-blebbistatin
analogs with crystallographic waters using a series of different
programs and scoring functions were explored. The outcomes
are summarized in Table 3. Included are all compounds
from Table 1 with their in silico optimized geometries.
Parent compound (S)-blebbistatin is included both with
its geometry as a co-crystallized ligand (entry BIT) and
with its in silico optimized geometry (entry (S)-1). When
comparing these results to experimental log IC50 values,
no strong correlations were found for ranks calculated by
MMGBSA (Figure 4), and for ranks by Consensus on score
(Figure 5).
Based on these results, structure-based methods for myosin II
seem to be limited in their ability to predict active compounds.
Only some of the largest molecules that do not fit into the
binding pocket are correctly rejected by some of the docking
programs. The total volume of the binding site, excluding
crystallographically-observed water molecules, is 417.77 Å3
according to the SiteMap module of the Schrödinger package.
This is indeed close to the volume of the largest ligand, (S)-14,
at 318.0 Å3.
This result obtained for the majority of the compounds
regardless of the docking program may reflect the
aforementioned difficult access to the binding site. The
protein structure complex with (S)-blebbistatin was therefore
studied using CAVER (Pavelka et al., 2016), an algorithm for the
detection of tunnels in macromolecules (Figure 6). Difficulty of
access to the binding site was confirmed, revealing a tight tunnel
that leads to the ligand as shown in Figures 6A,B. This tunnel is
lined by residues Arg 238, Glu 264, Ser 266, Arg 267, Phe 270, Ser
272, Glu 275, Ser 456, Glu 459, Phe 461, Val 463, Ser 465, Glu 467,
Gln 468, Cys 470, Ile 471, Thr 474, Lys 587, Tyr 634, Leu 262, Leu
263, Gln 271, Asn 464, Phe 466, Leu 469, and Asn 472, starting
from the surface of the protein toward the inside. These residues
may well be involved in limiting access of ligands to the binding
site.
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FIGURE 3 | Binding site of myosin II (in white) with co-crystallized ligand (S)-blebbistatin (BIT, cyan): (A) without water molecules, and (B) with explicit,
crystallographically-observed water molecules (in light blue).
TABLE 3 | Docking results with water molecules.
Compounda Glide XP Glide SP MMGBSA_dG_Bind Autodock 4 Autodock Vina Consensus
Scoreb Rank Scorec Rank Scored Rank Scoree Rank Scoref Rank On score On score rank On rank Rank on rank
BIT −12.65 9 −12.14 8 −73.50 3 −11.35 2 −12.9 2 −24.51 3 4.8 2
(S)-18 −13.23 2 −12.62 5 −70.28 4 −10.96 7 −12.2 8 −23.86 5 5.2 3
(S)-19 −12.19 13 −11.94 11 −63.91 8 −9.8 14 −12.3 6 −22.03 8 10.4 11
(S)-1 −12.62 10 −12.12 9 −75.25 2 −11.11 6 −12.3 6 −24.68 2 6.6 7
(S)-2 −12.79 8 −12.63 4 −67.36 7 −10.61 9 −11.4 11 −22.96 7 7.8 8
(S)-3 0 15 0 15 0 15 −9.32 17 −12.4 4 −4.34 16 13.2 14
(S)-4 −13.03 4 −12.34 7 −58.51 9 −10.18 11 −11.5 10 −21.11 9 8.2 9
(S)-5 −12.15 14 −9.62 14 −40.89 14 −10.11 12 −9.9 14 −16.53 14 13.6 16
(S)-6 −13.03 5 −12.69 3 −69.83 5 −11.2 4 −12.8 3 −23.91 4 4 1
(S)-7 0 15 0 15 0 15 −9.73 15 −9.5 15 −3.85 17 15 17
(S)-8 −14.04 1 −12.73 2 −68.77 6 −11.15 5 −11.3 12 −23.60 6 5.2 3
(S)-9 −12.45 12 −11.82 12 −48.96 12 −9.68 16 −9.5 15 −18.48 13 13.4 15
(S)-10 0 15 0 15 0 15 −8.72 18 −8.2 18 −3.38 18 16.2 18
(S)-11 0 15 0 15 0 15 −8.16 19 −7.8 19 −3.19 19 16.6 19
(S)-12 −12.49 11 −11.67 13 −54.21 10 −9.84 13 −9.4 17 −19.52 11 12.8 13
(S)-13 −13.14 3 −13.01 1 −77.04 1 −10.64 8 −10.4 13 −24.85 1 5.2 3
(S)-14 0 15 0 15 0 15 −6.34 20 −5.9 20 −2.45 20 17 20
(S)-15 0 15 0 15 0 15 −11.34 3 −12.4 4 −4.75 15 10.4 11
(S)-16 −12.83 6 −12.09 10 −51.78 11 −10.51 10 −11.9 9 −19.82 10 9.2 10
(S)-17 −12.83 7 −12.52 6 −45.63 13 −11.78 1 −13 1 −19.15 12 5.6 6
aStructures of compounds (S)-1 to (S)-19 are shown in Table 1. bGlide XP score (XP, kcal/mol). cGlide SP score (SP, kcal/mol). dMolecular Mechanics Generalized Born/Surface Area
Binding energy (MMGBSA_dG_Bind, kcal/mol). eAutodock4 binding energy (AD4, kcal/mol). fAutodock Vina score (Vina, kcal/mol).
Fingerprints
Chemical fingerprints describe in a digital manner a molecular
structure. ECFPs include a chemical awareness of substructures
in a compound due to the atom-type description of the
neighborhood of each atom in a molecule. The ECFPs for our
compound library were calculated and the distance between them
was computed. The results of the distances between fingerprints
for the study compounds as well as between each compound and
the two groups of compounds (actives: IC50 <10µM; inactives:
IC50 >10µM) are shown in Table 4.
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FIGURE 4 | Docking with crystallographic waters of study compounds:
correlation of log IC50 values (measured) and rank MMGBSA (calculated).
FIGURE 5 | Docking with crystallographic waters of study compounds:
correlation of log IC50 values (measured) and consensus on score rank
(calculated).
After encoding chemical structures, their dissimilarity
distance was calculated, with the distance to itself, i.e.,
identity = 0. Interesting results were found. All actives are
closer to the other actives than to the inactive compounds, i.e.,
they had smaller dissimilarity distances to the averages. This
was also the case when actives are excluded themselves from the
active group during the calculation, i.e., distance to all the other
actives, called “actives-self ” in Table 4, with the exception of
(S)-blebbistatin (S)-1. Similarity to the active compounds implies
a greater affinity for the specific targets of the known actives.
In this study, such compounds could thus exhibit specificity
toward inhibition of myosin II. Importantly, among the inactive
compounds, those molecules that were borderline active, i.e., had
measured IC50 values of 14.1µM ((S)-8) and 13.53µM ((S)-13),
were also the closest (least dissimilar) to the active chemicals.
FIGURE 6 | Top-view (A) and side-view (B) of the tight tunnel (blue spheres)
from the protein surface (in white) leading to the complexed ligand blebbistatin
(in cyan).
In the dataset, several inactive compounds possess
experimental IC50 values ≥ 300µM. The exact numerical
value have not been determined because of solubility limitations
and the exact IC50 in these instances has no significance.
Therefore, correlations with fingerprint dissimilarity distances
were investigated in more detail for only those compounds
with an IC50 value < 45µM. A good correlation was found
between the chemical fingerprint dissimilarity distances
to the average of the actives with the experimental IC50
values for the set with IC50 values < 45µM (Figure 7A).
For the subset of active compounds (IC50 < 10µM), a
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TABLE 4 | Distance between chemical fingerprints for each compound to the averages of active ((S)-5, (S)-12, (S)-18, and (S)-19) and inactive compoundsa.
Compound IC50 µM) Class (S)-1 (S)-5 (S)-12 (S)-19 (S)-18 Actives Actives-self
b
(S)-1 2.16 Active 0 0.339 0.3214 0.2692 0.2083 0.2276 0.2845
(S)-2 48.5 Inact. 0.2642 0.3692 0.4308 0.3934 0.3214 0.3558
(S)-3 300 Inact. 0.2642 0.3692 0.4062 0.3667 0.3214 0.3455
(S)-4 300 Inact. 0.2778 0.3788 0.4394 0.4032 0.3333 0.3665
(S)-5 9.41 Active 0.339 0 0.1695 0.4 0.4127 0.2642 0.3303
(S)-6 19.3 Inact. 0.2041 0.3279 0.3934 0.3509 0.3019 0.3156
(S)-7 57.6 Inact. 0.3103 0.25 0.3385 0.4 0.3871 0.3372
(S)-8 14.1 Inact. 0.22 0.3387 0.4032 0.3621 0.2157 0.3079
(S)-9 23.5 Inact. 0.3158 0.2812 0.3939 0.4062 0.3934 0.3581
(S)-10 300 Inact. 0.3276 0.3433 0.403 0.4394 0.4032 0.3833
(S)-11 300 Inact. 0.35 0.3623 0.4203 0.4559 0.4219 0.4021
(S)-12 0.94 Active 0.3214 0.1695 0 0.3051 0.3158 0.2224 0.2779
(S)-13 13.53 Inact. 0.1915 0.4032 0.3036 0.25 0.1875 0.2672
(S)-14 300 Inact. 0.2407 0.3731 0.2787 0.3443 0.3276 0.3129
(S)-15 300 Inact. 0.22 0.3906 0.377 0.3333 0.283 0.3208
(S)-16 19.04 Inact. 0.3393 0.4493 0.4154 0.377 0.3333 0.3829
(S)-17 17.81 Inact. 0.3148 0.4328 0.3968 0.3559 0.3091 0.3619
(S)-18 9.22 Active 0.2083 0.4127 0.3158 0.2642 0 0.2402 0.3155
(S)-19 1.96 Active 0.2692 0.4 0.3051 0 0.2642 0.2477 0.2944
Inactives 0.2743 0.3606 0.3814 0.3672 0.3165
aStructures of compounds (S)-1 to (S)-19 are shown in Table 1. bActives-self, Calculation with actives excluded themselves from the active group during the calculation, i.e., distance
to the average of all the other actives.
FIGURE 7 | Correlation of IC50 values (measured) and average chemical
fingerprint distance to actives (calculated): (A) For all compounds with an IC50
value < 45µM; (B) for all actives (IC50 < 10µM), to actives without that
particular compound included.
strong correlation was also obtained when comparing
experimental IC50 values of individual active compounds
with its chemical fingerprint distance to the subset of actives,
even without that active compound included (“actives-self,”
Figure 7B). In sum, the chemical fingerprint dissimilarity
distance calculation may be useful for selecting, solely from
structure, active blebbistatin analogs among a set of hypothetical
analogs.
ADME and Antitargets
All of the compounds under study were docked and interactions
were calculated against a battery of antitargets that have
physiological significance for experiments involving blebbistatin.
Interactions were collected against the pregnane X receptor
(PXR), sulfotransferase (SULT), and cytochrome P450
(CYP) isoforms 2A6, 2C9, and 3A4. Three different docking
programs were used: Schrödinger Glide XP, Autodock 4,
and Autodock Vina. The results are shown in Figure 8,
where compounds with interactions stronger than 0.5
kcal/mol than that recorded for the co-crystallized ligand
are shaded in black, interactions weaker than 0.5 kcal/mol
are shaded in white, and those within 1 kcal/mol (i.e., ±0.5
kcal/mol from that of the co-crystallized ligand) are shaded in
gray.
From Figure 8, it can be seen that most compounds interact
with PXR, SULT, and CYP 2C9 and 3A4. The compound
that hit the most number of anti-targets was (S)-14, while
several others had lower interaction profiles. The most active
compounds according to the fingerprint method, i.e., (S)-
1, (S)-5, (S)-12, (S)-18, and (S)-19, had low interaction
profiles against the anti-targets with total scores mostly lower
than 3.0.
All the compounds were docked against the androgen
receptor structure 1T7R. The results are shown in
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FIGURE 8 | Interaction matrix between proposed ligands and antitargets. Color code: black = 1.0; gray = 0.5, white = 0.0. Columns: A, Glide XP PXR; B, Glide XP
SULT; C, Glide XP CYP 2A6; D, Glide XP CYP 2C9; E, Glide XP CYP 3A4; F, Glide XP Total; G, Autodock 4 PXR; H, Autodock 4 SULT; I, Autodock 4 CYP 2A6; J,
Autodock 4 CYP 2C9; K, Autodock 4 CYP 3A4; L, Autodock 4 Total; M, Vina PXR; N, Vina SULT; O, Vina CYP 2A6; P, Vina CYP 2C9; Q, Vina CYP 3A4; R, Vina Total;
S, Grand Total.
Table 5. All of the compounds had interaction energies
weaker than the active control dihydrotestosterone. The
compounds that had interaction energies weaker than −7
kcal/mol were (S)-10, (S)-11, (S)-12, (S)-14, (S)-15, (S)-
16, (S)-17, and (S)-19. Among the active compounds,
(S)-12 and (S)-19 had the lowest interactions against this
receptor, which may help avoid this hormonal target and
system.
ADME results from FAF filters showed that all of the
compounds pass Lipinksi’s rule of five, as well as Veber
and Egan bioavailability rules. All of the compounds passed
the PAINS filters, which detect non-specific, assay-interfering
compounds, except (S)-18 with a warning on ortho-aniline. All
compounds passed Lilly’s filters, except warnings for (S)-7 (risk
as Michael acceptor), (S)-9 (phenolic ester or carbamate), and
(S)-11 (risk as Michael acceptor). Leeson values are normally
under 1.0 for drugs (Leeson and Springthorpe, 2007). For the
active compounds, (S)-5, (S)-12, and (S)-19 compounds had
interesting calculated Leeson values of −0.39, −0.39, and 0.09,
respectively. The compounds in our library with calculated
values higher than 1.0 were (S)-18, (S)-1, (S)-2, (S)-6, (S)-8,
and (S)-13.
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TABLE 5 | Docking scores with the Androgen receptora.
Compound Androgen receptor score (kcal/mol)
(S)-1 −8.43
(S)-2 −8.87
(S)-3 −7.61
(S)-4 −8.37
(S)-5 −8.08
(S)-6 −8.76
(S)-7 −8.07
(S)-8 −8.04
(S)-9 −7.98
(S)-10 −5.73
(S)-11 −5.34
(S)-12 −6.88
(S)-13 −8.21
(S)-14 –
(S)-15 –
(S)-16 –
(S)-17 –
(S)-18 −7.18
(S)-19 –
dihydrotestosterone −11.91
aStructures of compounds (S)-1 to (S)-19 are shown in Table 1.
CONCLUSIONS
A variety of in silico techniques were evaluated for their
potential to speed up the discovery of novel myosin II ATPase
inhibitors of the (S)-blebbistatin family with a superior
target and antitarget profile. First, a variety of methods were
assessed for the recovery of active ATPase inhibitors among a
series of analogs. Structure-based methods, both without and
with crystallographically-observed water molecules, did not
perform well. This may be attributed to unaccounted ligand
discrimination by steric and temporal restrictions in the path(s)
leading toward the binding site. Dissimilarity distances among
compounds calculated by extended chemical fingerprints,
however, showed good correlations with experimentally
determined ATPase activity and offer promise for the selection
of actives from hypothetical libraries of analogs. Additional
profiling against antitarget proteins with physiological
significance for myosin inhibitors (PXR, SULT, androgen
receptor, CYPs), and using ADME filters revealed that, for
the currently known analogs, compounds (S)-1, (S)-5, (S)-12,
(S)-18, and (S)-19 possess the best overall profile. The techniques
and conclusions from this paper may aid in accelerating
the discovery of more potent myosin II ATPase inhibitors
with appropriate target and antitarget profiles, enabling the
development of pharmacological tools for use in motility-related
diseases.
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